Shenzhen Chipscreen Biosciences Investor Relations

Shenzhen Chipscreen Biosciences Co., Ltd. engages in the research, development, and sale of original small molecule drugs. The company develops precursor compounds and original new drug product lines for the treatment of human diseases in five therapeutic areas, including cancer, metabolic diseases, autoimmune disorders, central nervous system disorders, and antivirals. It is developing chidamide, a subtype-selective benzamide inhibitor of histone deacetylase (HDAC) primarily targeting subtypes 1, 2, 3 of class I HDAC; chiglitazar, a new-generation insulin sensitizing candidate drug for the treatment of type 2 diabetes mellitus; and chiauranib, an aurora B/VEGFR/PDGFR /c-Kit/CSF1R inhibitor. The company also develops CS23546, a small molecule PD-L1 inhibitor for CS23546 is a small molecule PD-L1 inhibitor; CS32582, a highly selective small molecule allosteric inhibitor of tyrosine kinase 2; CS12192, a highly selective JAK3 kinase inhibitor; and other drugs, such as CS12088 and CS23074. Shenzhen Chipscreen Biosciences Co., Ltd. was founded in 2001 and is headquartered in Shenzhen, China.

Read Less